



# Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100, Non-Small Cell Lung Cancer

Protocol-ID: 1238 V1.2 (Short), ATEZ1200/CRBP6/NPAC100, NSCLC

## Indication(s)

- Lung Carcinoma, Non-Small Cell (non-squamous); ICD-10 C34.-

## Protocol classification

- Classification: alternative
- Intensity: Standard dose
- Therapy mode: First line
- Therapy intention: palliative

## Cycles

Cycle length 21 days, recommended cycles: 6

## Protocol sequences

- [IMpower130: ATEZ1200/CRBP6/NPAC100, NSCLC \(PID1238\) -|- ATEZ1200/CRBP6/NPAC100 - ATEZ1200 maint. \(PID1272\)](#)

## Risks

- Emetogenicity (MASCC/ESMO): high (>90%) Carboplatinkombination
- Emetogenicity (MASCC/ESMO): low (10-30%) Nab-paclitaxel
- Neutropenia: very high (>41%) °3-4: 44%
- Thrombocytopenia below 50 000/μl: very high (>41%) °3-4: 45%
- Anemia Hb below 8g/dl: high (16-30%) °3-4: 29%
- Diarrhea: CTC AE °3-4: 5%
- Fatigue: CTC AE °3-4: 6%
- Nausea: CTC AE °3-4: 3%

## Therapy

### Hydration: Balanced Crystalloid Solution

HYD

Access: peripheral venous

Hydration before, during, or after antitumor therapy

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Balanced Crystalloid Solution</b>	500 ml		i.v.	60 min	60 min before Atezolizumab (d1)
8,15	<b>Balanced Crystalloid Solution</b>	500 ml		i.v.	60 min	60 min before Nab-paclitaxel (d8,15)

**Antiemesis: Emetogenicity high (CRBP), FOSAP, GRAN i.v., DEXA i.v.****AE**

Access: peripheral venous

DGHO 2016, DKG 2016, MASCC/ESMO 2016, carboplatin-containing combination therapies

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Fosaprepitant</b>	150 mg	NaCl 0.9% 150 ml	i.v.	20 min	30 min before Atezolizumab (d1)
1	<b>Dexamethasone</b>	12 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Atezolizumab (d1)
1	<b>Granisetron</b>	1 mg	NaCl 0.9% 50 ml	i.v.	5 min	15 min before Atezolizumab (d1)
8,15	<b>Granisetron</b>	1 mg	NaCl 0.9% 50 ml	i.v.	5 min	15 min before Nab-paclitaxel (d8,15)

**Medical tumor therapy: ATEZ1200/CRBP6/NPAC100****CTX**

Access: peripheral venous

Atezolizumab, carboplatin, and nab-paclitaxel in non-small cell, non-plate epithelial lung cancer

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	<b>Atezolizumab</b>	1200 mg	NaCl 0.9% 250 ml	i.v.	60 min	Sequence
If the first infusion was well tolerated, the second infusion can be given over 30 minutes.						
1	<b>Carboplatin</b>	6 AUC	Dextrose 5% 250 ml	i.v.	30 min	Sequence
1,8,15	<b>Nab-paclitaxel</b>	100 mg/m <sup>2</sup> BSA	none	i.v.	30 min	Sequence

**Concomitant therapy supplements**

For highly emetogenic chemotherapy, additional olanzapine is recommended in the acute (day 1) and delayed phases (days 2-4) at a dosing of 5-10 mg per day (NCCN, ESMO, ASCO, Onkopedia; as of 6/24).

Granisetron instead of Dexamethasone for antiemesis on days 8 and 15 to avoid immunosuppression and the risk of infection due to Dexamethasone exposure.

**References**

- West H, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial., *Lancet Oncol* 2019 May 20; [PMID]
- Arbour KC, Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer., *J Clin Oncol* 2018 10 01;36(28):2872-2878 [PMID]

**Recommendations**

- 01/2023: [European Society for Medical Oncology](#)
- 02/2024: [National Comprehensive Cancer Network](#)



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 15.02.2024